Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Sets March Date for Shareholder Meeting

Premium

Vermillion said this week that it will hold its 2012 shareholder meeting on March 21.

The scheduling of the meeting had become an issue for the company recently, with Vermillion last week receiving a notice from the Nasdaq Stock Market that it was not in compliance with the exchange's listing rule that companies hold an annual shareholder meeting no later than one year after the end of their fiscal year.

Also last week, Vermillion shareholder George Bessenyei brought an action against the company in the Delaware Court of Chancery to force it to hold its annual meeting (PM 1/11/2013).

At the meeting, one board seat will be up for election. The company has nominated Roberta Della Vedova for election to the seat. Vedova is the vice president of human resources and head of global diagnostic sales at biotech firm eBiosciences. She was also a co-founder of tumor testing firm AlliedPath.

Bessenyei and his fellow shareholders Gregory Novak and Robert Goggin have filed documents indicating they plan to nominate Goggin for the open seat. Goggin is a lawyer and an owner and director of Philadelphia-based law firm Keller & Goggin.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.